Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (191-200 of 301) with videos related to

Pageof 31
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical ProceduresJames Chambers, Elle Pope, Kathy Bungay, et al.
Journal of Managed Care Pharmacy : JMCP|March 31, 2009
Standardizing quality assessment of observational studies for decision making in health careDiana I Brixner, Anke-Peggy Holtorf, Peter J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 14, 2025
Identifying the Influential Dynamic Inputs in Cost-Effectiveness AnalysesMelanie D Whittington, Joshua T Cohen, Peter J Neumann, et al.
The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.
Radiology|June 13, 2003
Cost-effectiveness of PET in the diagnosis of Alzheimer diseasePamela M McMahon, Sally S Araki, Eileen A Sandberg, et al.
Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.
Headache|August 20, 2005
Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatmentJeffrey S Brown, George Papadopoulos, Peter J Neumann, et al.
The American Journal of Managed Care|April 12, 2008
A strategic plan for integrating cost-effectiveness analysis into the US healthcare systemPeter J Neumann, Jennifer A Palmer, Norman Daniels, et al.
Health Affairs Scholar|February 25, 2026
FDA approvals of specialty drugs, 2000-2024Sophie E Knox, Claire H Brennan, Daniel E Enright, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Pageof 31

Showing results (191-200 of 301) with videos related to

Sort By:
Pageof 31
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical ProceduresJames Chambers, Elle Pope, Kathy Bungay, et al.
Journal of Managed Care Pharmacy : JMCP|March 31, 2009
Standardizing quality assessment of observational studies for decision making in health careDiana I Brixner, Anke-Peggy Holtorf, Peter J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 14, 2025
Identifying the Influential Dynamic Inputs in Cost-Effectiveness AnalysesMelanie D Whittington, Joshua T Cohen, Peter J Neumann, et al.
The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.
Radiology|June 13, 2003
Cost-effectiveness of PET in the diagnosis of Alzheimer diseasePamela M McMahon, Sally S Araki, Eileen A Sandberg, et al.
Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.
Headache|August 20, 2005
Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatmentJeffrey S Brown, George Papadopoulos, Peter J Neumann, et al.
The American Journal of Managed Care|April 12, 2008
A strategic plan for integrating cost-effectiveness analysis into the US healthcare systemPeter J Neumann, Jennifer A Palmer, Norman Daniels, et al.
Health Affairs Scholar|February 25, 2026
FDA approvals of specialty drugs, 2000-2024Sophie E Knox, Claire H Brennan, Daniel E Enright, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Pageof 31